Granules India gets 2 USFDA observations for Chantilly facility
New Delhi: Drug firm Granules India on Monday said the US health regulator has issued two observations after the inspection of the Chantilly facility of its US-based subsidiary.
"The United States Food and Drug Administration (USFDA) has completed inspection of the facility of Granules Pharmaceuticals, a wholly owned foreign subsidiary of the company located in Chantilly, Virginia, USA on June 25, 2021, with two minor observations," Granules India said in a statement.
This is a pre-approval inspection for the products filed from this facility, it added.
Read also: Granules India gets USFDA nod for Acetaminophen, Aspirin, Caffeine Tablets to treat migraine
"We will be responding to the two observations within the stipulated time period," Granules Pharmaceuticals Executive Director Priyanka Chigurupati said.
Read also: Granules India to provide 16 crore free Paracetamol tablets to Telangana
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.